CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	617,963	291,682	1,109,096	594,559
Depreciation	332	207	580	414
Research and development (including stock-based compensation (Note 7))	54,404	155,385	116,213	246,373
Total operating expenses	672,699	447,274	1,225,889	841,346
Loss from operations	(672,699)	(447,274)	(1,225,889)	(841,346)
Other (income) expense:
Interest income	(1,269)	(47)	(2,763)	(126)
Interest expense	118,365	303,218	230,545	407,637
Gain on legal dissolution of subsidiary	(10,234,501)		(10,234,501)
Total other expense	(10,117,405)	303,171	(10,006,719)	407,511
Net income (loss)	9,444,706	(750,445)	8,780,830	(1,248,857)
Net loss attributable to the noncontrolling interest	489	524	995	1,039
Net income (loss) applicable to Bion's common stockholders	$ 9,445,195	$ (749,921)	$ 8,781,825	$ (1,247,818)
Net income (loss) applicable to Bion's common stockholders per basic and diluted common share	$ 0.23	$ (0.02)	$ 0.21	$ (0.04)
Weighted-average number of common shares outstanding:
Basic and diluted	41,088,992	31,187,645	40,904,342	30,990,639